Maxim downgraded Cellectar Biosciences (CLRB) to Hold from Buy. Cellectar’s radiopharma pipeline, including the Phase 1-ready assets CLR-121225 and CLR-121125, were the key drivers for Cellectar, but as the company now seeks strategic alternatives for its assets, there is significant uncertainty regarding the future development of these programs, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Cellectar Biosciences Reports Q1 2025 Financials and Strategic Plans
- Cellectar Biosciences reports Q1 EPS (14c), consensus (16c)
- Cellectar Biosciences expects cash to fund operations in Q4 of 2025
- CLRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cellectar Biosciences announces plan to explore strategic alternatives